Rhythm Pharmaceuticals (RYTM) Shares Outstanding (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Shares Outstanding (Entity) of $68.4 million for Q1 2026, up 7.8% year-over-year from $63.5 million in Q1 2025, and up 1.84% quarter-over-quarter from $67.2 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Shares Outstanding (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Shares Outstanding (Entity) for 11 consecutive years, with $68.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 7.8% year-over-year to $68.4 million; the TTM figure through Mar 2026 stood at $68.4 million (up 7.8% YoY), while the FY2025 annual figure was $67.2 million, up 7.72% from the prior year.
- Shares Outstanding (Entity) grew to $68.4 million in Q1 2026 per RYTM's latest filing, from $67.2 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $68.4 million in Q1 2026 and bottomed at $50.4 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $60.1 million across 5 years, with a median of $61.0 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.38% — and 2023, when it rose 12.82%.
- Rhythm Pharmaceuticals' Shares Outstanding (Entity) stood at $56.6 million in 2022, then grew by 4.97% to $59.4 million in 2023, then rose by 4.99% to $62.4 million in 2024, then rose by 7.72% to $67.2 million in 2025, then climbed by 1.84% to $68.4 million in 2026.
- Business Quant data shows RYTM's Shares Outstanding (Entity) at $68.4 million in Q1 2026, $67.2 million in Q4 2025, and $66.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 68.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.59 Mn |
| Mar 31, 2026 | 67.97 Mn |
| Dec 31, 2025 | 64.98 Mn |
| Sep 30, 2025 | 66.26 Mn |
| Jun 30, 2025 | 63.68 Mn |
| Mar 31, 2025 | 63.06 Mn |
| Dec 31, 2024 | 61.00 Mn |
| Sep 30, 2024 | 61.22 Mn |
| Jun 30, 2024 | 61.01 Mn |
| Mar 31, 2024 | 60.14 Mn |
| Dec 31, 2023 | 57.67 Mn |
| Sep 30, 2023 | 57.87 Mn |
| Jun 30, 2023 | 56.87 Mn |
| Mar 31, 2023 | 56.71 Mn |
| Dec 31, 2022 | 52.12 Mn |
| Sep 30, 2022 | 51.40 Mn |
| Jun 30, 2022 | 50.40 Mn |
| Mar 31, 2022 | 50.33 Mn |
| Dec 31, 2021 | 49.60 Mn |
| Sep 30, 2021 | 50.25 Mn |